Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 1;44(1):166-197.
doi: 10.1097/FTD.0000000000000952.

Antifungal Drugs TDM: Trends and Update

Benjamin Kably  1   2 , Manon Launay  3 , Audrey Derobertmasure  1 , Sandrine Lefeuvre  4 , Eric Dannaoui  2   5 , Eliane M Billaud  1   2
Affiliations
Review

Antifungal Drugs TDM: Trends and Update

Benjamin Kably et al. Ther Drug Monit. .

Abstract

Purpose: The increasing burden of invasive fungal infections results in growing challenges to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an overview of recent advances in AF TDM.

Methods: We conducted a PubMed search for articles during 2016-2020 using "TDM" or "pharmacokinetics" or "drug-drug-interaction" with "antifungal," consolidated for each AF. Selection was limited to English language articles with human data on drug exposure.

Results: More than 1000 articles matched the search terms. We selected 566 publications. The latest findings tend to confirm previous observations in real-life clinical settings. The pharmacokinetic variability related to special populations is not specific but must be considered. AF benefit-to-risk ratio, drug-drug interaction (DDI) profiles, and minimal inhibitory concentrations for pathogens must be known to manage at-risk situations and patients. Itraconazole has replaced ketoconazole in healthy volunteers DDI studies. Physiologically based pharmacokinetic modeling is widely used to assess metabolic azole DDI. AF prophylactic use was studied more for Aspergillus spp. and Mucorales in oncohematology and solid organ transplantation than for Candida (already studied). Emergence of central nervous system infection and severe infections in immunocompetent individuals both merit special attention. TDM is more challenging for azoles than amphotericin B and echinocandins. Fewer TDM requirements exist for fluconazole and isavuconazole (ISZ); however, ISZ is frequently used in clinical situations in which TDM is recommended. Voriconazole remains the most challenging of the AF, with toxicity limiting high-dose treatments. Moreover, alternative treatments (posaconazole tablets, ISZ) are now available.

Conclusions: TDM seems to be crucial for curative and/or long-term maintenance treatment in highly variable patients. TDM poses fewer cost issues than the drugs themselves or subsequent treatment issues. The integration of clinical pharmacology into multidisciplinary management is now increasingly seen as a part of patient care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Cornely OA, Koehler P, Arenz D, et al. EQUAL Aspergillosis Score 2018: an ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses. 2018;61:833–836.
    1. Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases Community of practice. Clin Transpl. 2019;33:e13544.
    1. Nivoix Y, Ledoux MP, Herbrecht R. Antifungal therapy: new and evolving therapies. Semin Respir Crit Care Med. 2020;41:158–174.
    1. Houšť J, Spížek J, Havlíček V. Antifungal drugs. Metabolites. 2020;10:106.
    1. Miller R, Assi M; AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019;33:e13553.

LinkOut - more resources